TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06842498: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sponsor: Kyntra Bio · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 75 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06842498 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06842498 Rescue Dossier →